The price you pay for Epidiolex may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

GW Pharmaceuticals is closing in on a US filing for its cannabinoid epilepsy drug, Epidiolex, after trumpeting late-stage study findings. The company specialises in drugs derived from the cannabis ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought investors’ attention to the company’s appetite in dealmaking.

Professor O’Sullivan’s presentation, “A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex,” highlighted results from canine studies evaluating Artelo’s ...

GW contributed $991 million to Jazz's overall 2024 revenue, largely driven by its leading product, Epidiolex. This drug is a cannabidiol for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals JAZZ reported fourth-quarter 2024 adjusted earnings of $6.60 per share, which beat the Zacks Consensus Estimate of $5.79. Earnings rose 31% year over year. Total revenues rose 8% ...

The presentation will showcase Artelo’s recently obtained pharmacokinetic results in canine studies with the Company’s proprietary oral solid compositions of ART12.11 compared to Epidiolex.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced it is buying Chimerix (Nasdaq: CMRX) for $8.55 per share in cash, ...

Total revenues rose 8% year over year to $1.09 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.06 billion. See the Zacks ...